Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2018, inter alia, has recommended payment of dividend of Rs. 2/- (Rupees Two Only) per equity share of Re. 1/- each of the Company for the year ended March 31, 2018, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. The dividend is expected to be paid on or about last week of September, 2018. Ref: Clause 44(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 Pursuant to the requirements of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we enclose herewith the details of the result of remote e-voting and electronic voting conducted at the NCLT convened meeting of equity shareholders of Sun Pharmaceutical Industries Limited held on June 04, 2019 at 10:15 a.m. 1ST at Prof. Chandravadan C. Mehta Auditorium - General Education Centre, Maharaja Sayajirao University of Baroda, Near D. N. Hall, Pratap Gunj, Vadodara-390 002, Gujarat, India for approval of the Composite Scheme of Arrangement among Sun Pharmaceutical Industries Limited and Sun Pharma (Netherlands) B.V., and Sun Pharmaceutical Holdings USA Inc., and their respective members and creditors ('Composite Scheme of Arrangement') along with the Scrutinizer''s Report. The said Composite Scheme of Arrangement was approved by the requisite majority of equity shareholders through remote e-voting and electronic voting conducted at the Meeting. We request you to kindly take note of the same. (As Per BSE Announcement Dated on 05.06.2019) Intimation about NCLT Order on Scheme of Arrangement. For further details refer letter attached. (As Per BSE Announcement Dated 27.12.2019)